Carlos Alegret-Molina

This inventor holds 9 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 7 EPO patents. Top assignees: Esteve Pharmaceuticals, S.a., Laboratorios Del Dr. Esteve S.a.. Active years: 2018-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Carlos Alegret-Molina. Retrieved from https://idiyas.com/inventor/carlos-alegret-molina

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 2)

% Patents Active = 66.7

CIPO Patents = 2 (Patent Applications = 6)

EPO Patents = 7 (Patent Applications = 8)

Average Co-Inventor Count = 3.1

ph-index = 2

Forward Citations = 4(Granted Patents)

Location History:

Barcelone, ES (2019)
Barcelona, ES (2018 - 2023)

Company Filing History:

7 out of 34

Esteve Pharmaceuticals, S.a.

patents

2 out of 150

Laboratorios Del Dr. Esteve S.a.

patents

Years Active: 2018-2023

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11649248 - Oxadiazaspiro compounds for the treatment of drug abuse and addiction (2023-05-16),

2. 10927128 - Oxadiazaspiro compounds for the treatment of drug abuse and addiction (2021-02-23),

3. 10703765 - Alkyl and aryl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain (2020-07-07),

4. 10689398 - OXA-Diazaspiro compounds having activity against pain (2020-06-23),

5. 10421750 - Substituted morpholine derivatives having activity against pain (2019-09-24),

6. 10246465 - Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain (2019-04-02),

7. 10183918 - Oxa-azaspiro compounds having activity against pain (2019-01-22),

8. 10065971 - Amide derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain (2018-09-04),

9. 10022359 - 1,9-diazaspiro undecane compounds having multimodal activity against pain (2018-07-17),

Title: Innovations by Carlos Alegret-Molina – A Focus on Oxadiazaspiro Compounds

Introduction

Carlos Alegret-Molina, based in Barcelona, Spain, is a prominent inventor known for his significant contributions to pharmacological research. With a remarkable portfolio of nine patents, he stands out in the field of drug treatment, particularly concerning addiction.

Latest Patents

Among his most notable inventions are the oxadiazaspiro compounds aimed at treating drug abuse and addiction. These compounds exhibit pharmacological activity towards the sigma (σ) receptor, offering potential therapeutic benefits. His work includes the development of processes for the preparation of these compounds, as well as creating pharmaceutical compositions that integrate them. The applications of these inventions aim to provide new avenues for therapy, particularly for addressing issues related to drug abuse and addiction.

Career Highlights

Carlos has had an impactful career, working with reputable companies such as Esteve Pharmaceuticals and Laboratorios Del Dr. Esteve. His experience in these organizations has undoubtedly contributed to the success of his innovations and the enhancement of drug therapies.

Collaborations

Alegret-Molina’s journey in innovation has been enriched by collaborations with talented professionals. Notable coworkers include Marina Virgili-Bernado and Carmen Almansa-Rosales, who have contributed to the advancement of his research and development projects.

Conclusion

Carlos Alegret-Molina continues to make strides in the realm of pharmaceutical innovation with his patented oxadiazaspiro compounds. His work holds promise for the future, particularly in developing effective treatments for drug abuse and addiction, showcasing the vital role of inventors in advancing medical science.

Profile summary based on public USPTO records.